Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations by van Duin, David & Bonomo, Robert A.
Clinical Infectious Diseases
I N V I T E D A R T I C L E




David van Duin1 and Robert A. Bonomo2,3,4,5
1Division of Infectious Diseases, University of North Carolina, Chapel Hill; 2Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 3Division of Infectious Diseases
and HIV Medicine, Department of Medicine, 4Department of Molecular Biology and Microbiology, and 5Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland,
Ohio
Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel β-lactam/β-lactamase combination antibiotics. The antimicrobial
spectrum of activity of these antibiotics includes multidrug-resistant (MDR) gram-negative bacteria (GNB), including Pseudomonas
aeruginosa. Ceftazidime/avibactam is also active against carbapenem-resistant Enterobacteriaceae that produce Klebsiella pneumoniae
carbapenemases. However, avibactam does not inactivate metallo-β-lactamases such as New Delhi metallo-β-lactamases. Both cefto-
lozane/tazobactam and ceftazidime/avibactam are only available as intravenous formulations and are dosed 3 times daily in patients
with normal renal function. Clinical trials showed noninferiority to comparators of both agents when used in the treatment of com-
plicated urinary tract infections and complicated intra-abdominal infections (when used with metronidazole). Results from pneumo-
nia studies have not yet been reported. In summary, ceftolozane/tazobactam and ceftazidime/avibactam are 2 new second-generation
cephalosporin/β-lactamase inhibitor combinations. After appropriate trials are conducted, they may prove useful in the treatment of
MDR GNB infections. Antimicrobial stewardship will be essential to preserve the activity of these agents.
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A number of important initiatives have been introduced to ad-
dress the issue of multidrug-resistant (MDR) bacteria. In addi-
tion to the “bad bugs, no drugs” and the “10 × ’20” initiatives of
the Infectious Disease Society of America, a comprehensive
plan to combat the rise of antibiotic-resistant bacteria called
Combating Antibiotic-Resistant Bacteria was recently released
[1–3]. This plan describes the need to develop “at least 2 new
antibiotic drug candidates, non-traditional therapeutics, and/
or vaccines from pre-clinical testing to clinical trials for treat-
ment or prevention of human disease” by 2020.
The concerns regarding antibacterial resistance, especially in
clinically important gram-negative bacteria (GNB), are contin-
uing to increase worldwide [4, 5]. A better understanding of the
epidemiology of this multifaceted epidemic is needed. In the
long term, prevention of spread of MDR GNB is most impor-
tant. Meanwhile, however, patients will continue to present with
difficult-to-treat infections caused by MDR GNB. Treatment
choices for these infections have been limited, especially for in-
fections caused by bacteria that produce carbapenemases and/
or extended-spectrum β-lactamases (ESBLs) [6–8].
Ceftolozane/tazobactam and ceftazidime/avibactam are 2 an-
tibiotics with anti-GNB activity that were recently approved for
the treatment of complicated intra-abdominal infections
(cIAIs) and complicated urinary tract infections (cUTIs) by
the US Food and Drug Administration (FDA). Their character-
istics will be reviewed, with a focus on their respective antimi-
crobial spectra and currently available clinical trial data.
CHEMISTRY AND MODE OF ACTION
Ceftolozane/tazobactam combines a novel cephalosporin with
an established β-lactam β-lactamase inhibitor, whereas ceftazi-
dime/avibactam couples a well-known cephalosporin with a
novel non-β-lactam β-lactamase inhibitor. Both tazobactam
and avibactam target the active site of serine β-lactamases
(Table 1). Tazobactam, a β-lactam sulfone, binds irreversibly
to the active site of β-lactamases. The details of the process
are quite complex as there is also a small amount of hydrolysis
of tazobactam by certain class A β-lactamases such as SHV-1.
In contrast, avibactam is a diazabicyclooctane non-β-lactam
that binds covalently and reversibly to β-lactamases [9]. This
reversibility is a unique feature that allows avibactam to un-
dergo recyclization to inactivate another β-lactamase. The
crucial advantage of avibactam is its ability to inhibit ESBLs,
AmpC β-lactamases (as expressed in Pseudomonas aeruginosa
and Enterobacteriaceae), and class A carbapenemases of the
Klebsiella pneumoniae carbapenemase (KPC and OXA-48)
family [10].
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Ceftolozane and ceftazidime are structurally similar cephalo-
sporins (Figure 1). Ceftolozane is an oxyimino-aminothiazolyl
cephalosporin with a pyrazole substituent at the 3-position side
chain instead of the lighter pyridium present in ceftazidime.
This heavier side-chain provides improved steric hindrance to
prevent hydrolysis mediated through AmpC β-lactamases
[11]. Porin loss significantly increases in vitro minimum inhib-
itory concentration (MIC) values of ceftazidime, but appears to
have no effect on the efficacy of ceftolozane [12]. This porin loss
is described in a minority of clinical isolates and results in low-
level resistance to ceftazidime/avibactam (MIC =∼8 mg/L).
ANTIMICROBIAL ACTIVITY
Overall Spectrum of Activity
Ceftolozane/tazobactam and ceftazidime/avibactam have simi-
lar spectra of antimicrobial activity, but with some important
differences. Their primary activity is against aerobic GNB. For
gram-positive bacteria, both cephalosporin combinations have




TEM-1, TEM-2, SHV-1 A Penicillins, early cephalosporins Yes Yes
TEM-3, SHV-2 CTX-M-14 A Extended-spectrum cephalosporins, monobactams Yes Yes
KPC-2, KPC-3 A Broad spectrum including carbapenems No Yes
IMP-1, NDM-1, VIM-1 B Broad spectrum including carbapenems, but not monobactams No No
Escherichia coli AmpC C Cephalosporins High concentrations Yes
OXA-48 D Carbapenems No Yes
Abbreviation: KPC, Klebsiella pneumoniae carbapenemase
Figure 1. Chemical structures of ceftolozane, tazobactam, ceftazidime, and avibactam.
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some antistreptococcal, very limited antistaphylococcal, and no
antienterococcal activity. Both agents have in vitro activity
against selected anaerobic bacteria, including Fusobacterium
species and Propionibacterium species. However, activity
against Bacteroides species is less predictable, and Clostridium
species are resistant [13, 14]. Consequently, in clinical trials
evaluating the use of ceftolozane/tazobactam and ceftazidime/
avibactam in cIAI, metronidazole was added [15–17].
Importantly, both ceftolozane/tazobactam and ceftazidime/
avibactam are active against P. aeruginosa. In contrast, Acineto-
bacter and Stenotrophomonas species are generally resistant
[18–20]. Pending appropriate clinical trials, both combinations
have most promise for use in infections caused by MDR Pseu-
domonas species and MDR Enterobacteriaceae.
Spectrum of Activity Against Selected MDR GNB
Studies outlining the in vitro activity of ceftazidime/avibactam
and ceftolozane/tazobactam against Escherichia coli, K. pneu-
moniae, and P. aeruginosa are summarized in Tables 2 and 3.
Clinically, the key microbiologic difference between ceftazi-
dime/avibactam and ceftolozane/tazobactam is that avibactam
inhibits carbapenemases of the KPC family [10].
In a large in vitro study, ceftazidime/avibactam was tested
against >20 000 clinical US Enterobacteriaceae isolates [36]. Only
11 isolates displayed a ceftazidime/avibactam MIC > 8 µg/mL.
Two of these 11 isolates expressed metallo-β-lactamases (MBLs),
which are known to be resistant to avibactam-mediated inhibition
[36]. These data suggest that ceftazidime/avibactam will be a very
useful addition to the quite limited number of antibiotics currently
available to treat KPC-producing carbapenem-resistant Enterobac-
teriaceae (CRE). A concern to note is that avibactam-resistant var-
iants of SHV-1 and KPC-2 containing single point mutations are
known. These avibactam-resistant variants have amino acid
changes that are described in inhibitor-resistant SHVs and
TEMs. However, these KPC-2 variants also display decreased car-
bapenemase activity [37]. Fortunately, the combination of ceftazi-
dime/avibactam still maintains activity as the inhibitor-resistant
β-lactamases are less able to hydrolyze the oxyimono-cephalosporin
partner. Of greater concern are New Delhi metallo-β-lactamase
1–producing Enterobacteriaceae, which are increasingly common
in the Indian subcontinent and the Balkan countries [38].
Noncarbapenemase β-lactamases that are inhibited by avibac-
tam include class A, class C, and some class D β-lactamases.
Ceftazidime/avibactam has excellent in vitro activity against
ESBL-producing Enterobacteriaceae [36, 39]. In contrast, only
58% of ESBL-producingK. pneumoniae isolates from patients with
pneumonia had a ceftolozane/tazobactam MIC≤ 8 µg/mL [19].
Around 78% of abdominal and urinary clinical ESBL-producing
K. pneumoniae isolates demonstrated a ceftolozane/tazobactam
MIC ≤ 8 µg/mL [18]. Ceftolozane/tazobactam has reliable
Table 2. In Vitro Susceptibility of Selected Subsets of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa to Ceftazidime/Avibactam
Isolates (No.)
Ceftazidime/Avibactam
ReferenceMIC50 MIC90 % S
KPC-producing Enterobacteriaceae (129) 0.5 2 100 [21]
KPC-producing Enterobacteriaceae (120) 0.25 1 97.5 [22]
Escherichia coli (6486) 0.06 0.12 100 [22]
E. coli (375) 0.06 0.12 100 [23]
ESBL-producing E. coli (90) 0.12 0.25 100 [23]
Gentamicin-resistant E. coli (166) 0.12 0.25 100 [24]
Klebsiella pneumoniae (4421) 0.12 0.25 99.9 [22]
K. pneumoniae (254) 0.12 0.5 100 [23]
ESBL-producing K. pneumoniae (84) 0.25 1 100 [23]
Pseudomonas aeruginosa (5328) 2 4 96.8 [25]
Meropenem-nonsusceptiblea P. aeruginosa (396) 8 32 67.4 [25]
Non-ICU P. aeruginosa (2240) 2 4 97.5 [21]
ICU P. aeruginosa (842) 2 8 95.6 [21]
Meropenem-nonsusceptible P. aeruginosa (537) 4 16 87.0 [21]
Ceftazidime-nonsusceptible P. aeruginosa (482) 4 16 80.7 [21]
P. aeruginosa (3902) 2 4 97 [26]
MDR P. aeruginosa (580) 4 16 81 [26]
XDR P. aeruginosa (338) 8 32 74 [26]
P. aeruginosa (1743) 2 8 96.3 [27]
P. aeruginosa (881)b 2 8 95.8 [28]
Gentamicin-resistant P. aeruginosa (131) 4 16 88 [24]
β-lactam–resistant P. aeruginosa (55) 2 32 84 [29]
Abbreviations: ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug resistant; MIC50, minimal inhibitory concentration
that inhibits growth of 50% of the test population; MIC90, minimal inhibitory concentration that inhibits growth of 50% of the test population; S, susceptible; XDR, extensively drug resistant.
a These isolates were also nonsusceptible to ceftazidime, cefepime, and piperacillin/tazobactam.
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activity against Enterobacteriaceae that produce the globally im-
portant ESBLs CTX-M-14 and CTX-M-15 [33].
However, when considering these in vitro susceptibilities,
previous reports of treatment failures of piperacillin/tazobactam
in serious infections caused by ESBL-producing organisms sug-
gest that caution should be used when considering treatment of
such infections with ceftolozane/tazobactam until clinical data
become available [40].
Ceftolozane/tazobactam shows potent in vitro activity against
Pseudomonas species, although baseline resistance is already de-
tectable. Between 86% and 95% of clinical P. aeruginosa isolates
show a ceftolozane/tazobactam MIC ≤ 8 µg/mL [18, 19, 30].
When evaluating specifically more resistant strains, 60%–80%
ceftazidime-resistant and meropenem-resistant pseudomonal
isolates displayed MICs to ceftolozane/tazobactam of ≤8 µg/
mL [18, 19, 30].
Similarly, ceftazidime/avibactam has potent in vitro antipseu-
domonal activity; 84%–97% of clinical isolates had a ceftazidime/
avibactam MIC≤ 8 µg/mL in several large studies [20, 41, 42].Of
note, in a study on archived Pseudomonas isolates—collected >10
years before the release of avibactam—a resistance rate of 18%
was found [29]. Resistance was found to be mediated by de-
creased cell wall permeability and increased efflux, rather than
changes in penicillin-binding protein or novel β-lactamases.
This further emphasizes the ongoing struggle of treating infec-
tions caused by MDR Pseudomonas species. The mechanism of
Table 3. In Vitro Susceptibility of Selected Subsets of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa to Ceftolozane/Tazobactam
Isolates (No.)
Ceftolozane/Tazobactam
ReferenceMIC50 MIC90 % S
Escherichia coli (3843) 0.25 0.5 99.2 [30]
ESBL-producing E. coli (715) 0.5 4 95.7 [30]
E. coli (2691) 0.25 0.5 99.3 [31]
ESBL-producing E. coli (327) 0.5 4 94.5 [31]
E. coli (1306) NR 0.5 98 [32]
E. coli (368) 0.25 1 98.6 [19]
ESBL-producing E. coli (76) 0.5 4 93.4 [19]
E. coli (341) 0.25 0.5 98.5 [18]
CTX-M-15–producing E. coli (219) <0.25 0.5 100 [33]
E. coli (250) 0.25 0.5 100 [34]
Klebsiella pneumoniae (1408) 0.5 >32 82.7 [30]
ESBL-producing K. pneumoniae (493) 2 >32 78.7 [30]
Meropenem-nonsusceptible K. pneumoniae (140) >32 >32 1.4 [30]
K. pneumoniae (1298) 0.25 16 89.1 [31]
ESBL-producing K. pneumoniae (244) 32 >32 41.8 [31]
Meropenem-nonsusceptible K. pneumoniae (100) >32 >32 4 [31]
K. pneumoniae (1205) NR 4 89 [32]
K. pneumoniae (370) 0.25 >32 84.9 [19]
ESBL-producing K. pneumoniae (132) 4 >32 57.6 [19]
K. pneumoniae (126) 0.25 16 88.9 [18]
Pseudomonas aeruginosa (2435) 0.5 1 99 [35]
Ceftazidime-nonsusceptible P. aeruginosa (398) 1 4 94.5 [35]
Meropenem-nonsusceptible P. aeruginosa (401) 1 4 96.5 [35]
P. aeruginosa (2191) 1 >32 86.3 [30]
MDR P. aeruginosa (698) 4 >32 57.4 [30]
XDR P. aeruginosa (538) 32 >32 46.3 [30]
P. aeruginosa (1971) 0.5 2 98.5 [31]
Ceftazidime-nonsusceptible P. aeruginosa (338) 4 8 91.1 [31]
Meropenem-nonsusceptible P. aeruginosa (388) 1 8 92.8 [31]
P. aeruginosa (1257) NR 2 97 [32]
P. aeruginosa (1019) 0.5 4 94.1 [19]
Ceftazidime-nonsusceptible P. aeruginosa (269) 4 >32 77.7 [19]
Meropenem-nonsusceptible P. aeruginosa (268) 2 >32 78 [19]
P. aeruginosa (500) 0.5 4 94.4 [34]
Ceftazidime-nonsusceptible P. aeruginosa (120) 2 >64 80.8 [34]
Meropenem-nonsusceptible P. aeruginosa (177) 2 32 85.3 [34]
P. aeruginosa (212) 0.5 4 93.4 [18]
Abbreviations: ESBL, extended-spectrum β-lactamase; MDR, multidrug resistant; MIC50, minimal inhibitory concentration that inhibits growth of 50% of the test population; MIC90, minimal
inhibitory concentration that inhibits growth of 90% of the test population; NR, not reported; S, susceptible; XDR, extensively drug resistant.
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efflux and decreased cell wall permeability can pose a significant
threat to all future drug development.
PHARMACOKINETICS
Dosing
Both ceftolozane/tazobactam and ceftazidime/avibactam are
available for intravenous use only. The currently approved dos-
ages for adult patients with an estimated creatinine clearance
>50 mL/minute are ceftolozane 1 g with tazobactam 500 mg
every 8 hours and ceftazidime 2 g with avibactam 500 mg every
8 hours. Both drugs are primarily cleared through the kidneys,
and the dosages have to be renally adjusted (Table 4). Both are dia-
lyzable and the dose that is scheduled near hemodialysis should be
given after hemodialysis in patients with end-stage renal disease.
Ceftolozane/Tazobactam
The maximum plasma concentration of ceftolozane occurs at
around an hour after the start of infusion. The mean plasma
half-life of ceftolozane is 2.7 hours in healthy, uninfected adults,
and significant accumulation does not occur after multiple doses
[43]. This relatively short half-life accounts for the need to ad-
minister a dose every 8 hours. Ceftolozane is excreted through
the kidneys with minimal metabolism and appears as parent
compound in the urine. The clearance of tazobactam, which
has been extensively previously reviewed, does not appear to be
influenced when coadministering ceftolozane [44]. This is in
contrast to coadministration with piperacillin, which leads to a
decrease in clearance of tazobactam with a corresponding in-
crease in the area under the curve (AUC) [43, 45]. The steady-
state volume of distribution of ceftolozane is 12.9 L, which is
close to the average extracellular volume, suggesting potential
therapeutic levels at extracellular sites of infection. The volume
of distribution was found to be increased in patients with obesity,
and further increased in patients with infection [46].
Ceftolozane/tazobactam is currently being studied for use in
pneumonia. In this context, the pharmacokinetics in the lung
were evaluated in healthy volunteers and compared to those
of piperacillin/tazobactam [47]. The ratio of epithelial lining
fluid (ELF) to plasma AUC of ceftolozane was comparable to
that of piperacillin (0.48 vs 0.26, respectively). The ELF concen-
trations of ceftolozane exceeded 8 mg/L for >60% of the dosing
interval, suggesting that the growth of susceptible Pseudomonas
species should be inhibited in the lungs. Of note, the tazobac-
tam concentration was 2-fold higher in ELF when given with
piperacillin as compared to ceftolozane. This is unlikely to be
of much importance in lower respiratory tract infections caused
by Pseudomonas species—as tazobactam adds little to the anti-
pseudomonal effect of ceftolozane—but it may be important
when treating β-lactamase–producing Enterobacteriaceae in
the lungs.
Ceftazidime/Avibactam
The pharmacokinetics of ceftazidime/avibactam are similar to
those of ceftolozane/tazobactam. The primary route of elimina-
tion is renal excretion for both ceftazidime and avibactam, re-
sulting in high levels of the parent compounds in the urine. The
pharmacokinetics of ceftazidime are known for most patient
populations [48]. In brief, the steady-state volume of distribu-
tion is around 15 L, and only 10%–17% of drug is protein-
bound. The half-life is around 1.5 hours, and peak plasma
concentrations occur 30 minutes after intravenous infusion of
ceftazidime [48, 49].
Similarly, avibactam plasma concentrations also peak shortly
after infusion with a maximum noted at 30–60 minutes after
start of infusion, followed by a biphasic decrease [50]. In the
same study of 32 healthy volunteers, elderly (defined as age
≥65 years) men but not elderly women were found to have a
lower maximum concentration (Cmax) of avibactam compared
with young adults (defined as age 18–45 years); elderly men had
a mean Cmax of 26 µg/mL compared with 34–38 µg/mL in the
young and elderly female cohorts [50].As this was a small study
in healthy volunteers, the clinical relevance of this finding re-
mains to be determined. The half-life of avibactam ranged
from 1.7 to 3.2 hours; this tended to be somewhat longer in
the elderly adults. The volume of distribution of avibactam
ranged from 15 L to 24 L [50].
Even in supratherapeutic doses, ceftazidime/avibactam did
not increase QT duration in healthy male volunteers [51]. Ad-
verse events were observed in 30% of volunteers who received
the supratherapeutic dose of ceftazidime 3000 mg with avibac-




In a phase II cUTI study, 86 patients received ceftolozane dosed
at 1 g every 8 hours and 43 patients were treated with ceftazi-
dime. Microbiological cure rates in the ceftolozane (83%) and
ceftazidime (76%) arms were comparable. Adverse events in
the ceftolozane vs ceftazidime arms included constipation (9%
vs 5%), sleep disorder (7% vs 5%), and diarrhea (4 vs 7%) [52].















>50 1000/500 q8h >50 2000/500 q8h
30–50 500/250 q8h 31–50 1000/250 q8h
15–29 250/125 q8h 16–30 750/190 q12h
ESRD on
hemodialysisa
500/250 × 1 loading dose,
followed by 100/50 q8h
6–15 750/190 q24h
<6a 750/190 q48h
Abbreviation: ESRD, end-stage renal disease.
a Give after completion of hemodialysis on hemodialysis days.
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In phase III cUTI trials, ceftolozane/tazobactam (n = 398) was
compared to levofloxacin (n = 402) [53].Of note, in vitro fluoro-
quinolone resistance at baseline was seen in more than a quarter
of uropathogens, whereas baseline resistance to ceftolozane/
tazobactam was only found in 2.7% of isolates. Clinical cure
and microbiological eradication were required for the composite
cure outcome. Superiority of ceftolozane/tazobactam compared
with levofloxacin was found in both the modified intention-to-
treat (mITT) analysis (77% vs 68%), as well as in the per-protocol
(83% vs 75%) analysis. In contrast, outcomes were similar when
only patients with baseline levofloxacin-susceptible pathogens
were analyzed. Rates of adverse events were similar; headache oc-
curred in 6% vs 5%, constipation in 4% vs 3% [53].
In a phase II cIAI study, 83 patients were randomized to cef-
tolozane/tazobactam plus metronidazole vs 39 patients to mer-
openem [15].While not statistically significant, the clinical cure
rate in the microbiologically mITT (m-mITT) population—
those patients who received at least 1 dose of study medication
and had a bacterial pathogen isolated from cultures—was numer-
ically lower in the patients treated with ceftolozane/tazobactam
plus metronidazole; clinical cure was observed in 51 of 61
(84%) patients vs 24 of 25 (96%) patients in the meropenem
arm (difference, −12%; 95% confidence interval [CI], −35%
to 11%). Adverse event rates were similar [15].
In 2 large multicenter phase 3 cIAI randomized controlled
trials, patients were randomized to ceftolozane/tazobactam
plus metronidazole (n = 389) vs meropenem (n = 417) [16]. A
numerically lower cure rate was again observed in the m-mITT
analysis: 83% vs 87% (weighted difference, −4.2%; 95% CI,
−9% to 0.5%) in patients treated with ceftolozane/tazobactam
plus metronidazole vs meropenem, respectively. However, this
difference was not statistically significant and the 95% CI did
not include the a priori noninferiority boundary of a 10% dif-
ference. Of note, in patients with moderate renal failure (creat-
inine clearance, 30–50 mL/minute), a numerically lower cure
rate was noted in the phase 3 intra-abdominal infection trial:
11 of 23 (48%) in the ceftolozane/tazobactam plus metronidazole
arm vs 9 of 13 (69.2) in the meropenem arm. The decreased cure
rate in the patients aged ≥65 years (69% vs 82%) was also
thought to be secondary to changes in renal clearance. These
findings prompted the FDA to include a warning in the package
insert of ceftolozane/tazobactam to monitor renal function at
least daily in patients with changing renal function and to change
ceftolozane/tazobactam dosing as needed.
Reported adverse events included hypokalemia (2.9%), head-
ache (2.5%), and increased alanine aminotransferase (2.5%) and
aspartate aminotransferase (1.6%) levels [16].
Ceftazidime/Avibactam
In a phase 2 trial on cUTIs, 68 patients received ceftazidime/
avibactam and 67 were randomized to imipenem/cilastatin [54].
The dosing was 500 mg of ceftazidime and 125 mg of avibactam
every 8 hours. More than 90% of patients were infected with
E. coli. In the clinically evaluable population (n = 64), a favorable
clinical response was observed in 24 of 28 (86%) of patients in the
ceftazidime/avibactam arm vs 29 of 36 (81%) in the imipenem/
cilastatin arm. Microbiological responses were evaluated in the
microbiologically evaluable population (n = 62); 19 of 27 (70%) pa-
tients had a favorable microbiological response in the ceftazidime/
avibactam arm vs 25 of 35 (71%) in the imipenem/cilastatin arm.
Drug-related serious adverse events were uncommon: 1 of the 68
(1.5%) patients treated with ceftazidime/avibactam developed
acute renal failure and another patient developed diarrhea.
A cIAI phase 2 trial compared ceftazidime/avibactam plus
metronidazole (n = 101) vs meropenem (n = 102) [17]. Note
that the dosing for this trial was 4 times higher than the dos-
ing in the UTI study; 2 g of ceftazidime was given with 500 mg
of avibactam every 8 hours. This is also the dose that is rec-
ommended in the package insert for patients with normal
renal function. Clinical response rates were comparable in the
m-mITT population: 82% (70/85 patients) in the ceftazidime/
avibactam plus metronidazole arm vs 88% (79/89 patients) in
the meropenem arm (difference, −6.4%; 95% CI, −23.8% to
6.0%). In this trial the predominant pathogen was also E. coli,
which represented 69% of GNB. Gastrointestinal side effects
such as nausea (10% vs 6%), vomiting (14% vs 5%), and abdom-
inal pain (8% vs 3%) were more common in the ceftazidime/
avibactam plus metronidazole group compared with the mero-
penem group [17]. This was likely due to the metronidazole
component of the therapy. The pooled results of 2 phase 3 trials
comparing ceftazidime/avibactam plus metronidazole vs mero-
penem in adult hospitalized patients with cIAI were recently
presented [55]. Again, noninferiority to meropenem was es-
tablished. In the mITT analysis, 83% of 520 patients in the
ceftazidime/avibactam plus metronidazole arm had a clinical
cure, compared to 85% of 523 patients receiving meropenem.
In the clinically evaluable population, clinical cure rates were
higher: 92% vs 93% in the ceftazidime/avibactam plus metroni-
dazole vs meropenem arms, respectively [55]. Notably, sub-
group analysis indicated that patients with moderate renal
impairment (estimated creatinine clearance between 30 and
50 mL/minute) had lower cure rates in the ceftazidime/avibac-
tam plus metronidazole arm (45%) vs the meropenem arm
(74%). This may have been secondary to an observed delay in
dose readjustment back to full dosing in patients with recovery
of renal function [56]. Importantly, the dosing strategy used in
these phase 3 cIAI trials for moderate renal failure was 1000/
250 mg ceftazidime/avibactam every 12 hours. The current pack-
age insert recommendations are to give 1000/250 mg ceftazidime/
avibactam every 8 hours to patients with moderate renal failure.
FORMULARY CONSIDERATIONS
Both ceftolozane/tazobactam and ceftazidime/avibactam will be
most useful in the treatment of infections caused by MDR GNB.
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The need for these agents is limited in patients with cUTI and
cIAI caused by bacteria with a more favorable susceptibility pat-
tern. However, the incidence of MDR GNB is increasing at an
alarming pace, and these 2 agents represent important additions
to currently available antibiotics.
For both drugs there is an issue of preexisting in vitro resis-
tance. The percentages of Enterobacteriaceae and Pseudomonas
species that are resistant to these antibiotics is likely to dramat-
ically increase following their widespread clinical use, as it has
for virtually any other antibiotic. We are in need of reliable clin-
ical data to evaluate the role of ceftazidime/avibactam in the
treatment of CRE. However, extrapolating from its in vitro
activity, its safety profile, and the known clinical efficacy of
β-lactam antibiotics, there is great promise that the outcomes
of patients infected with KPC-producing CRE will improve. It
would be terrible if we were to lose the opportunity to treat fu-
ture critically ill patients because of overuse in patients with in-
fections caused by more susceptible organisms. Therefore, the
introduction into hospital formularies should be considered
with great care and the appropriate restrictions should be put
in place.
The need for either ceftolozane/tazobactam or ceftazidime/
avibactam will vary greatly from hospital to hospital, depending
on the population that they serve and specifically on their local
antibiogram. Hospitals that have low rates of multidrug resis-
tance in their isolates of P. aeruginosa and Enterobacteriaceae
will have a limited need for these drugs.
In summary, ceftolozane/tazobactam and ceftazidime/avi-
bactam are second-generation cephalosporin/β-lactamase in-
hibitor combinations with potential to improve outcomes of
patients infected with MDR GNB. Pathogen-specific random-
ized trials are needed to determine the efficacy in those settings.
If overused, widespread resistance is likely to evolve rapidly by
the selection of resistant strains.
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